Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service

Histopathology

Volumn 54, Issue 4, 2009, Pages 428-432

  Faratian, Dana ^a   Graham, Ashley ^b   Rae, Frances ^a   Thomas, Jeremy ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; FISH; Her 2; Scoring; TMA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SAFETY; SCREENING TEST; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TIME FACTORS; TISSUE ARRAY ANALYSIS;

EID: 62149123263     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03257.x     Document Type: Article

References (14)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N. Engl. J. Med. 2001 344 783 792.
2. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer. N. Engl. J. Med. 2005 353 1673 1685.
3. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N. Engl. J. Med. 2005 353 1659 1672.
4. Joenesu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant doxatel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006 354 809 820.
5. Hayes DF, Thor AD, Dressler LG et al. Her2 and response to Paclitaxel in node-positive breast cancer. N. Engl. J. Med. 2007 357 1496 1506.
6. Graham AD, Faratian D, Rae F, Thomas JStJ. Tissue microarray technology in the routine assessment of Her-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 2008 52 847 855.
7. Varshney D, Zhou YY, Geller SA, Alsabeh R. Determination of Her-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am. J. Clin. Pathol. 2004 121 70 77.
8. Lal P, Salazar PA, Hudis C, Ladanyi M, Chen B. Her-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization. Am. J. Clin. Pathol. 2004 121 631 636.
9. Walker RA, Bartlett JMS, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 2008 61 818 824.
10. Ginestier C, Charafe-Jauffret E, Penault-Llorca F et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J. Pathol. 2004 202 286 298.
11. Chieh Lan MS, Ming Liu J, Tsang-Wu L et al. Erb-B2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am. J. Clin. Pathol. 2005 124 97 102.
12. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of Her-2/neu gene amplification in breast cancer with an emphasis on tumours with borderline and low level amplification. Am. J. Clin. Pathol. 2005 123 237 243.
13. Dudding N, Hewer EM, Lancucki L, Rice S. Rapid screening: a comparative study. Cytopathology 2001 12 235 248.
14. Grogan TM, Pestic-Dragovich L, McElhinney A et al. Interpretative guide for Ventana Inform Her-2 DNA probe staining for breast carcinoma. Tucson. AZ : Ventana Medical Systems, Inc., 2007 10 11.